scholarly journals Analysis of Relationships between DAT1 Polymorphism Variants, Personality Dimensions, and Anxiety in New Psychoactive Substance (Designer Drug) (NPS) Users

Genes ◽  
2021 ◽  
Vol 12 (12) ◽  
pp. 1977
Author(s):  
Jolanta Chmielowiec ◽  
Krzysztof Chmielowiec ◽  
Jolanta Masiak ◽  
Tomasz Pawłowski ◽  
Dariusz Larysz ◽  
...  

The use of ‘new psychoactive substances’ appears to be increasingly common. The aim of this study was to examine biological and personality determinants in individuals who choose to use these substances, which may help in the prevention and treatment of psychoactive substance use disorders. The study group consisted of 374 male volunteers; all were users of ‘new psychoactive substances’ (NPS). The NPS users were recruited after they had abstained—for at least 3 months—from any substance of abuse in addiction treatment facilities. The NPS patients and the control subjects were examined by a psychiatrist using the Mini-International Neuropsychiatric Interview (M.I.N.I.), the NEO Five-Factor Personality Inventory (NEO-FFI), and the State-Trait Anxiety Inventory (STAI) scales. The real-time PCR method was used for genotyping. When we compared the controls with the study group, statistically significant interactions were found between DAT1 polymorphism, neuroticism, and NPS use. NPS use and DAT1 polymorphism were associated with a higher level of neuroticism on the NEO-FFI scale. The study group of NPS users showed a higher severity of anxiety symptoms, both in terms of trait and state, compared to the control group. The results may support the idea that neuroticism and anxiety correlate strongly with coping motives for using NPS.

2019 ◽  
Vol 17 (0) ◽  
pp. 21-35
Author(s):  
Sandra Valantiejienė ◽  
Regina Saveljeva

Purpose – The purpose of the article is to describe the transformations in the perceptions of the consequences of the use of psychoactive substances between 9-12’th grades pupils in the context of the implementation of the psychoactive substances abuse prevention program “My Way”. Research methodology – the authors performed a quasi-experiment and according to the methodological requirements related to the use of such scientific method in the educology studies, used an unequal control group and the primary/initial (pre-test) as well as final (post-test) measurements to achieve the aim of the research/article. Findings – the data of the quasi-experiment research showed that as the whole after intervention the pupil’s perceptions about the use of psychoactive substances in the experimental group has changed; the pupils who were assigned to the control group assessed the effects of the use of psychoactive substances better than those who were assigned to the control group. Research limitations – during the implementation of the program and the experiment, the activities related to the quasi-experiment were held only by social pedagogues in certain selected schools and classes (considering various factors such as the behaviour of children or their attributability to the families at social risk). Accordingly, in the next similar studies, children can be sampled evenly, without differentiating them based on their behavioural problems. Practical implications – the results of the research could be used in practice in the following ways: (i) by motivating the schools of general education in the Republic of Lithuania to choose prevention programs as the purposeful and meaningful instrument to develop healthy life skills; (ii) to develop and expand the range of new prevention programs based on the experience of the program “My Way” which is presented and evaluated in this article. Originality/Value – there are no similar previous educological and other educational science studies (in Lithuania) how the pupils’ attitudes change during the pre-planned and systematically implemented preventive activities in general education schools; the article presents and outlines the experience and practice of the first such Lithuanian program for the prevention of psychoactive substance abuse (“My Way”).


2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Jolanta Chmielowiec ◽  
Agnieszka Boroń

Abstract Introduction: Disorders in the field of reward system neurotransmission are mentioned as one of the most important causes of addiction. Genetic variation is assigned a special role. The literature on the subject mentions primarily the genes of dopamine neurotransmission: DAT (dopamine transporter), DRD2 (dopamine receptor D2), DRD4 (dopamine receptor D4). However, so far there are few literature reports on these genes in the context of innovators in addiction therapy. The aim: Analysis of the relationship between the variability of specific polymorphisms in the DRD2 (rs1799732), ANKK1 (rs1800497), DAT (rs28363170), DRD4 (exon 3 - VNTR) genes with the occurrence of relapses in people addicted to psychoactive substances. Material and methods: The research was carried out on a group of 301 people addicted to psychoactive substances staying in an addiction therapy center in Lubuskie and Zachodniopomorskie voivodships in Poland. The control group consisted of 301 people with no diagnosed addiction to psychoactive substances nor mental disorders. The study of polymorphisms DRD2 (rs 1799732), ANKK1 (rs1800497) was performed by real-time PCR method; whereas DAT (rs28363170), DRD4 (exon 3 - VNTR) was genotyped by PCR and the amplified products were visualized using ethidium bromide stained gel electrophoresis (3% agarose) and UV photography. Results: This study showed that in addicts genotype frequencies of the VNTR polymorphism in the third exon of human DRD4 were as follow: S/L in 33.55%, S/S - 63.12% and L/L 3.32%; while in the control group S/L - 32.56%, S/S - 58.8 % and L/L -8.6% (χ2 = 7.617, p = 0.022). Significant differences in the frequency of DRD2 gene polymorphism rs1799732 were observed (frequency of alleles; χ2 = 5.48, p = 0.0192) and DRD4 VNTR polymorphism (χ2 = 7.687, p = 0.021) between the addicted to psychoactive substances who have a one-time stay in an inpatient treatment center and the control group.


2019 ◽  
Vol 38 (1) ◽  
pp. 269-276 ◽  
Author(s):  
Zhenhua Qian ◽  
Cuimei Liu ◽  
Jian Huang ◽  
Qingqing Deng ◽  
Zhendong Hua

Abstract Purpose This publication reports analytical properties of the designer benzodiazepine 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (flualprazolam) seized in an anesthesia robbery case. Methods The target compound was identified by liquid chromatography–quadrupole time-of-flight-mass spectrometry (LC–QTOF-MS), gas chromatography–mass spectrometry (GC–MS), and nuclear magnetic resonance (NMR) spectroscopy. Results We could obtain detailed analytical data of flualprazolam—a new designer benzodiazepine available on the designer drug market. Conclusions More designer benzodiazepines have been detected and seized on the illegal drug scene as new psychoactive substances during the last 5 years. In this study, we presented analytical data of flualprazolam to assist forensic laboratories that encounter these newly emerging compounds in casework. This is the first report on this compound in illegal products.


Author(s):  
Arnis Slesars ◽  
Aija Jermacāne

A new psychoactive substance is defined as a new narcotic or psychotropic drug, in pure form or in preparation, that is not controlled by the United Nations drug conventions (1961, 1971), but which may pose a public health threat comparable to that posed by substances listed in these conventions. The author researched and analyzed: 1.History of new psychoactive substances in Latvia; 2.Legislative approaches for restricting new psychoactive substances in Latvia; 3.Advantages and disadvantages of criminal liability against new psychoactive substances in Latvia.


Author(s):  
Andrejs Vilks

In the century of modern technologies the human behaviour models are changing, new types of addiction are developing, including addiction to processes (cyber, games addiction), as well as addiction to new substances. Among young people there is observed an increased spreading of new psychotropic substances, manufacturing of which is very simple, but their realization determines possibilities for a markedly great profit. In the cultural environment of young people the new traditions are formed, specific elements of subculture, positive attitude towards being able to use and apply something new. A new value system is developing with a sense of unlimited freedom and extensive rights. Along with the chances to buy and use new psychoactive substances, the changes occur also in the young people’s psyche, affecting their emotional and physical condition. A new, socially-pedagogical approach is needed in restriction of the use of these new psychoactive substance.


2020 ◽  
Vol 9 (11) ◽  
pp. 3593
Author(s):  
Jolanta Masiak ◽  
Jolanta Chmielowiec ◽  
Krzysztof Chmielowiec ◽  
Anna Grzywacz

Background: Approximately 25–50% of people diagnosed with substance use disorder experience psychiatric disorders, and this percentage is even higher if subclinical psychopathological symptomatology is taken into consideration. ”Dual diagnosis” implies the comorbidity of two disorders (mental disorder and addiction), but in a clinical setting, numerous dual diagnoses involve multiple addictions (polysubstance use means the concurrent use of more than one psychoactive substance). Clinical observations and epidemiological studies showed that the use of stimulants in combination with other substances results in additional risks. Apart from the clinical significance of the specificity of stimulants used in combination with other substances, only non-exhaustive research on the specificity of this comorbidity has been performed to date. The aim of the study was to analyze polymorphisms of the genes (DRD4 VNTR in exon III Ex3, DRD2 rs1076560, rs1800498, rs1079597, rs6276, as well as in the PROM promoter region (rs1799732, ANKK1 Tag1A rs1800497, DAT) in a group of patients diagnosed with polysubstance use disorder, including addiction to stimulants, and the co-occurrence of specific mental disorders in a group of patients diagnosed with polysubstance use disorder, including addiction to stimulants, compared to the group of patients diagnosed with polysubstance use disorder. Methods: The study group consisted of 601 male volunteers with psychoactive substance dependence (n = 300) and non-dependent controls (n = 301). The genomic DNA was extracted from venous blood using standard procedures. Genotyping was conducted with the real-time PCR method. All computations were performed using STATISTICA 13. Results: Psychotic disorders were significantly more common in the group of males with polysubstance addiction, including addiction to stimulants, compared to the group of males with polysubstance addiction without addiction to stimulants. In our own research, different statistical significances were found in the frequency of the DRD4 Ex3 gene polymorphism: s/s was more common in the study group. Psychotic disorders were more common in people addicted to stimulants compared to people addicted to other substances. Conclusions: In our study, psychotic disorders occurred more frequently in the study group of patients with polysubstance addiction, including addiction to stimulants, compared to the control group of patients with polysubstance addiction, but with no addiction to stimulants. Different statistical significances were found in the frequency of the DRD4 Ex3 gene polymorphism: s/s was more common in the study group, while the l/l genotype was less frequent in the study group. In DRD2 PROM rs 1799732, the del allele occurred more often than the ins allele in the study group. In the DRD4 Ex3 gene polymorphism, the s allele was more common in the study group, and the l allele was less frequent. In the DRD4 Ex3 gene polymorphism for the s/s genotype, psychotic disorders and generalized anxiety were more common, while for the s/l and l/l genotype, they were less frequent. The DRD4 Ex3 polymorphism s alleles were more common for depressive episode, dysthymia, and psychotic disorders as well as generalized anxiety disorder. We see a clear genetic aspect here. However, we want to be careful and draw no definite conclusions.


2020 ◽  
Vol 7 (4) ◽  
pp. 104-109
Author(s):  
Dr. Neeraj J. Karandikar ◽  
Dr. Prasad K. Tagad

Background: Substance abuse problems can be described as developing through a set of progressive stages.  The adolescent period, it self is more vulnerable for beginning of various substance abuse. Adolescents usually begin to use legal drugs like tobacco, alcohol and then cannabis and other illicit drugs.  Objective: To determine the socio-demographic profile of substance using children and adolescents in a community setting.  Methods: 150 families were selected using systematic sampling with random start from a well-defined community. The study was carried out in two phases. In phase I 74 families were identified who had children in this age group 10-19 yrs. There were total of 141 children in this age group. They were further screened for substance use through interview of parents and children. In Phase II, Children who had been found to have used some psychoactive substance were taken in the case study group. Similar number of children who were not using any psychoactive substance was selected for control group from the same 150 families. Both the study group children and control group children were evaluated in detail for Sociodemographic information & nature and extent of substance use by using ICD-10 Diagnostic Criteria For Research. Results: The mean age of the both groups was comparable and males predominated (60.5%) in both group. In both groups, educational level was similar but there was higher number of children who were currently attending school in the control group. Majority of school drop-outs were seen from the study group. (57.9% as compared to 28.9% in the control group). This was statistically significant. ). The prevalence of substance use was found to be around 27%. In our study the most commonly used substance was tobacco & Mishri was the most common form used.  Chewing tobacco, cigarette and gutkha were various other tobacco containing products used. Further, Mishri was more commonly used by females, while cigarette and gutkha were more commonly used by males.  Of the 23 tobacco dependent children 20 were above the age of 16 years. This finding was statistically significant. (P < 0.05). Only the males were found to use alcoholic beverages and all these boys were above the age of 16 years, Beer was the most common form used. Conclusion: Study findings can be used to generate awareness in the community regarding antecedents of substance abuse and the problems arising from it.  Community based-longitudinal studies are needed to understand multiple factors influencing alcohol use and recommend targeted preventive measures.


2018 ◽  
Vol 26 (3) ◽  
pp. 179-185 ◽  
Author(s):  
Magdalene HY Tang ◽  
LY Hung ◽  
CK Lai ◽  
CK Ching ◽  
Tony Wing Lai Mak

Background: New psychoactive substances are constantly evolving structural analogues of traditional drugs of abuse that have become a threat to public health worldwide and within our locality. An understanding of the local pattern of new psychoactive substance use will help guide frontline clinical management. Objectives: This study was conducted to review the new psychoactive substances detected in cases referred to the authors’ laboratory (a tertiary clinical toxicology centre), as well as the associated clinical features and toxicological findings. Methods: All cases referred to the laboratory for toxicology analysis between January 2009 and December 2017, and which were analytically confirmed to involve new psychoactive substance use, were retrospectively reviewed. Demographic data, clinical features and toxicology findings were studied. Results: A total of 111 cases involving 104 patients and 22 types of new psychoactive substances were identified, with an increasing trend in the number of cases and subclass of new psychoactive substances detected. Up to half of the cases (n = 64) were related to the use of 2-phenyl-2-(ethylamino)-cyclohexanone (2-oxo-PCE, a ketamine analogue); other new psychoactive substances detected included para-methoxymethamphetamine, 4-fluoroamphetamine, phenazepam, 3-trifluoromethylphenylpiperazine, 5-methoxy-diisopropyltryptamine, 2-diphenylmethylpyrrolidine, methoxyphenidine, the N-methoxybenzyl drugs, cathinones, synthetic cannabinoids and opioids. Among the acute poisoning cases attributable to new psychoactive substance use, the severity was fatal (n = 3), severe (n = 17), moderate (n = 67) and minor (n = 17). And 11 patients required intensive care unit admission. All three fatal cases were associated with para-methoxymethamphetamine use. Conclusion: A rising trend of new psychoactive substance use is observed locally, which is associated with considerable morbidity and mortality. Continued vigilance from frontline clinicians and medical professionals is imperative in the combat against new psychoactive substance use.


2017 ◽  
Vol 50 (03) ◽  
pp. 116-122 ◽  
Author(s):  
Norbert Scherbaum ◽  
F. Schifano ◽  
Udo Bonnet

AbstractOver the last few years, hundreds of new psychoactive substances (NPS) have been identified in Europe. Apart from some herbal compounds, NPS mainly include synthetic cannabinoids and a range of new synthetic stimulants (e. g., cathinones). Synthetic NPS are often developed whilst modifying the basic chemical (e. g., phenethylamine or tryptamine) structure. Although the pharmacology and toxicology of most NPS are hardly known, they are being offered, especially online, as “bath salts,” as “incense mixtures,” or under other misleading labels. In addition, NPS are advertised as “legal highs,” suggesting that, in contrast to substances regulated by the national laws, trading with NPS is legal. Although only little is known about the prevalence of NPS use, some of these molecules may be associated with a range of severe adverse reactions. Indeed, different from cannabis, synthetic cannabinoid users may present with epileptic seizures, loss of consciousness, and a range of persisting psychopathological disorders. Future studies should inform better-tailored management strategies.


2019 ◽  
Author(s):  
Emil Bartosz Rozenek ◽  
Karolina Wilczyńska ◽  
Monika Górska ◽  
Napoleon Waszkiewicz

INTRODUCTION.In Poland, an increasing number of psychoactive substances are becoming prohibited by law as psychotropic or narcotic substances, or as new psychoactive substances (NPSs). Owing to the enormous technological possibilities offered by today's science, synthesis of new derivatives of prohibited compounds is no longer a problem. The moment a dangerous substance is outlawed, new designer drugs (in Poland known as ‘dopalacze’) appear on the market. STATE OF KNOWLEDGE.An amendment to the Act on Counteracting Drug Addiction issued in July 2018 made it possible for the NPS to be considered drugs by law. Synthetic cannabinoids and cathinone derivatives make up the majority of NPSs identified by the authorities in Poland. Synthetic cannabinoids which can, unlike cannabinoid receptor agonists of plant origin, cause death by somatic toxicity, are particularly dangerous. The ability to quickly recognize poisoning with synthetic opioids is crucial, since an antidote reversing the depressive effect of opioids on the respiratory center can be administered. SUMMARY.This work collects the most important and up-to-date information on designer drugs, based on reports and articles published between 2015 and 2019. The covered aspects include: the current definition of designer drugs in relation to the Polish law, their exact division due to the clinical effects they cause and the description of the threats they pose. Emphasis was given to the current situation of the designer drug market in Poland.


Sign in / Sign up

Export Citation Format

Share Document